Nisha Holay

Nisha Holay

University of Texas Austin - Austin / United States
Natural Sciences / Molecular Biology & Genetics
AD Scientific Index ID: 5318310
University of Texas at Austin
person_outline Nisha Holay's MOST POPULAR ARTICLES
1-) Covalent JNK inhibitor, JNK-IN-8, suppresses tumor growth in triple-negative breast cancer by activating TFEB-and TFE3-mediated lysosome biogenesis and autophagyM Soleimani, A Somma, T Kaoud, R Goyal, J Bustamante, DC Wylie, ...Molecular Cancer Therapeutics 21 (10), 1547-1560, 2022102022
2-) First-in-human dose-escalation study of the novel oral depsipeptide class I-targeting HDAC inhibitor bocodepsin (OKI-179) in patients with advanced solid tumorsAR Schreiber, JA Kagihara, BR Corr, SL Davis, C Lieu, SS Kim, A Jimeno, ...Cancers 16 (1), 91, 202332023
3-) Elucidating the role of HDACs in T cell biology and comparing distinct HDAC inhibitors in augmenting responses to cancer immunotherapyTA Triplett, N Holay, S Kottapalli, C VanDenBerg, A CapassoThe Journal of Immunology 204 (1_Supplement), 165.23-165.23, 202032020
4-) Elucidating the direct effects of the novel HDAC inhibitor bocodepsin (OKI-179) on T cells to rationally design regimens for combining with immunotherapyN Holay, A Somma, M Duchow, M Soleimani, A Capasso, S Kottapalli, ...Frontiers in Immunology 14, 1260545, 202312023
5-) Longitudinal COVID-19 immune trajectories in patients with neurological autoimmunity on anti-CD20 therapySA Bazzi, C Maguire, N Holay, J Geltman, K Hurley, C DiPasquale, ...Multiple Sclerosis and Related Disorders 68, 104195, 202212022